Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.201
-0.059 (-4.68%)
Jan 31, 2025, 4:00 PM EST - Market closed
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 420 Lexington Avenue, Suite 2446 New York, New York 10170 United States | |
| Phone | 347-627-0058 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chairman, Chief Executive Officer and President |
| Jaime Bartushak | Chief Financial Officer and Treasurer |
| Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
| Myron Z. Holubiak | Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 27, 2025 | 10-K/A | [Amend] Annual report |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 27, 2024 | 10-K | Annual Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 13, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |
| Sep 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |